Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies
Allied on Aimmune’s peanut allergy med, Nestlé is betting big on the biotech after the Phase III efficacy data pointed to an NDA filing with the FDA next month. Their timeline projects a potential market launch in H2 of next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.